|
|
 Previous Article | Table of Contents | Next Article 
Cytomegalovirus-specific T-cell immunity in recipients of autologous
peripheral blood stem cell or bone marrow transplants
P Reusser, R Attenhofer, H Hebart, C Helg, B Chapuis and H Einsele
Department of Medicine, University Hospital, Basel, Switzerland.
The cytomegalovirus (CMV)-specific CD8+ cytotoxic T-lymphocyte (CTL) and
CD4+ T-helper cell (Th) functions were characterized in 15 CMV seropositive
recipients of autologous peripheral blood stem cell or bone marrow
transplants. These immune functions were evaluated in peripheral blood
specimens obtained before and at 1, 2, and 3 months after transplant. For
study of CTL activity, blood mononuclear cells were cocultured with
CMV-infected autologous fibroblasts for 2 weeks and then tested for
cytotoxicity against CMV-infected or mock-infected autologous and
HLA-mismatched fibroblasts. The Th response to CMV antigen was assessed by
standard lymphoproliferative assay. CMV- specific CD8+ CTL and CD4+ Th
responses were detectable in 12 (80%) and 14 (93%) patients, respectively,
in the first 3 months after transplantation. A Th response to CMV was
always present by the time of first CTL detection. During the
posttransplant period, CMV infection occurred in 6 (40%) patients, and
detection of CMV-specific CD8+ CTL activity was associated with protection
from subsequent CMV infection (P = .002). Among CMV seropositive autograft
recipients, CMV-specific CD8+ CTL and CD4+ Th responses are restored in a
large proportion of patients in the first 3 months after transplantation,
and the presence of a specific CD8+ CTL activity affords protection from
CMV infection.
Volume 89,
Issue 10,
pp. 3873-3879,
05/15/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Yue, A. Kaur, M. K. Eberhardt, N. Kassis, S. S. Zhou, A. F. Tarantal, and P. A. Barry
Immunogenicity and Protective Efficacy of DNA Vaccines Expressing Rhesus Cytomegalovirus Glycoprotein B, Phosphoprotein 65-2, and Viral Interleukin-10 in Rhesus Macaques
J. Virol.,
February 1, 2007;
81(3):
1095 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yue, A. Kaur, S. S. Zhou, and P. A. Barry
Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65).
J. Gen. Virol.,
April 1, 2006;
87(Pt 4):
777 - 787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Seggewiss, K. Lore, E. Greiner, M. K. Magnusson, D. A. Price, D. C. Douek, C. E. Dunbar, and A. Wiestner
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
Blood,
March 15, 2005;
105(6):
2473 - 2479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kondo, Y. Akatsuka, K. Kuzushima, K. Tsujimura, S. Asakura, K. Tajima, Y. Kagami, Y. Kodera, M. Tanimoto, Y. Morishima, et al.
Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles
Blood,
January 15, 2004;
103(2):
630 - 638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yue, S. S. Zhou, and P. A. Barry
Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques
J. Gen. Virol.,
December 1, 2003;
84(12):
3371 - 3379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Papanicolaou, J.-B. Latouche, C. Tan, J. Dupont, J. Stiles, E. G. Pamer, and M. Sadelain
Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele
Blood,
October 1, 2003;
102(7):
2498 - 2505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Reusser, H. Einsele, J. Lee, L. Volin, M. Rovira, D. Engelhard, J. Finke, C. Cordonnier, H. Link, and P. Ljungman
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
Blood,
February 15, 2002;
99(4):
1159 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.A. Sosman, P. Stiff, S.M. Moss, P. Sorokin, B. Martone, R. Bayer, K. van Besien, S. Devine, W. Stock, D. Peace, et al.
Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Post-Stem-Cell Infusion
J. Clin. Oncol.,
February 1, 2001;
19(3):
634 - 644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Holmberg, M. Boeckh, H. Hooper, W. Leisenring, S. Rowley, S. Heimfeld, O. Press, D. G. Maloney, P. McSweeney, L. Corey, et al.
Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation
Blood,
December 15, 1999;
94(12):
4029 - 4035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Guillaume, D. B. Rubinstein, and M. Symann
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Blood,
September 1, 1998;
92(5):
1471 - 1490.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Boeckh and G. Boivin
Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications
Clin. Microbiol. Rev.,
July 1, 1998;
11(3):
533 - 554.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
